Markets:

Overview

News

Currencies

International

Treasuries

Harrow, Inc. - Common Stock (NQ:HROW)

41.12 +1.34 (+3.37%)

Streaming Delayed Price Updated: 10:54 AM EST, Dec 2, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Harrow, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45% ↗

November 27, 2025

Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position.

Via The Motley Fool

Topics Regulatory Compliance

Outset Medical, Gemini Space Station, CoreWeave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 11, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

November 10, 2025

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside ↗

September 26, 2025

Via Stocktwits

Demystifying Harrow: Insights From 5 Analyst Reviews ↗

September 23, 2025

Via Benzinga

A Preview Of Harrow's Earnings ↗

August 08, 2025

Via Benzinga

Could Harrow's New Sedation Pill Change Millions Of Medical Procedures Forever? ↗

September 26, 2025

Harrow, Inc. (NASDAQ: HROW), a U.S.-based provider of ophthalmic disease management solutions, announced on Friday that it has agreed to acquire Melt

Via Benzinga

Tesla To Rally Around 4%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

September 23, 2025

Via Benzinga

HARROW INC (NASDAQ:HROW) Presents High Growth Momentum and Technical Breakout Opportunity ↗

August 29, 2025

Harrow Inc (HROW) is a high-growth ophthalmic pharma stock with strong revenue expansion and a bullish technical breakout setup, signaling potential upward momentum.

Via Chartmill

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

August 17, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

August 13, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

August 09, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

August 05, 2025

From Pomerantz LLP

Via GlobeNewswire

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

August 01, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

July 28, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

July 23, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

July 18, 2025

From Pomerantz LLP

Via GlobeNewswire

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

July 17, 2025

From Harrow, Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

July 16, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

July 14, 2025

From Pomerantz LLP

Via GlobeNewswire

This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

July 11, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

July 10, 2025

From Pomerantz LLP

Via GlobeNewswire

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

July 06, 2025

From The Schall Law Firm

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

July 06, 2025

From Pomerantz LLP

Via GlobeNewswire

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

June 18, 2025

From Harrow, Inc.

Via Business Wire

William Blair Bullish On Harrow's High-Margin Branded Eye Drug Strategy ↗

June 11, 2025

Harrow licensed U.S. rights to FDA-approved BYQLOVI for post-surgical eye pain and adds momentum to its branded ophthalmic drug strategy.

Via Benzinga

Assessing Harrow: Insights From 4 Financial Analysts ↗

June 10, 2025

Via Benzinga

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

June 09, 2025

From Harrow, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.